Abstract

BackgroundJuvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The treatment of JIA has been revolutionized by the use of biologic agents. The use of biosimilar...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB1423 USE OF BIOSIMILAR THERAPIES IN ADULT PATIENTS DIAGNOSED WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE SPANISH REGISTRY OF ADVERSE EVENTS WITH BIOLOGIC THERAPIES (BIOBADASER)
D Ruiz Montesinos ... C Rodríguez-Lozano
Annals of the Rheumatic Diseases | VOL. 82
D Ruiz Montesinos, et. al.D Ruiz Montesinos ... C Rodríguez-Lozano
30 May 2023
Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis
John M Inadomi ... Annette Kwon
Gastrointestinal Endoscopy | VOL. 74
John M Inadomi, et. al.John M Inadomi ... Annette Kwon
24 Sep 2011
AB1129 Radiological cervical spine involvement in juvenile idiopathic arthritis in adulthood
D Peixoto ... F Teixeira
Annals of the Rheumatic Diseases | VOL. 71
D Peixoto, et. al.D Peixoto ... F Teixeira
01 Jun 2013
AB0446 SAFETY OF BIOLOGICAL THERAPIES: DATA FROM THE BIOBADAGUAY REGISTRY
C Vega ... A Amarilla
Annals of the Rheumatic Diseases | VOL. 82
C Vega, et. al.C Vega ... A Amarilla
30 May 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers